Dr. Marc Lemonnier, co-founder and CEO of Antabio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Antabio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 8AM PST, 11AM EST, 4PM GMT, 5PM CET on March 9.
The webcast will explore some of the technologies and companies tackling the emerging antibiotic resistance crisis. Participants will learn about established approaches to combat antibiotic resistance — including antibiotic-resistance breakers, macrocycles and other antibiotic classes for infections caused by key pathogens such as carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this vital topic.
Dr. Marc Lemonnier is a life sciences entrepreneur and a molecular microbiologist by training, and has led Antabio to develop a rich portfolio of novel Gram-Negative anti-infective programs. Other webcast participants include:
Dr. Prabhavathi Fernandes, Founder, President and CEO of Cempra Inc.
Professor Anthony R.M. Coates, Chief Scientific Officer of Helperby Therapeutics
Dr. David Huang, Chief Medical Officer of Motif Bio
Dr. Glenn Dale, Head of Early Development, Antimicrobials of Polyphor
Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval by 2021. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. The Company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio